Rexahn Pharmaceuticals, Inc. RNN, a clinical stage pharmaceutical
company dedicated to developing and commercializing first-in-class oncology
therapeutics, today announced that it has been issued a United States patent
(No. 8,314,100), titled “1-[6,7-substituted alkoxyquinoxalinyl)
aminocarbonyl]-4-(hetero) arylpiperazine derivatives.”
This new patent covers Rexahn's quinoxalinyl-piperazine compounds, the process
for the preparation of such compounds and their pharmaceutical composition.
The patent includes Rexahn's RX-5902, a first-in-class p68 helicase inhibitor,
that is an orally available new chemical entity exhibiting potent antitumor
properties in several types of tumors. RX-5902 has also shown to possess
strong anti-proliferative activity against known anti-cancer drug-resistant
cancer cells, and a synergistic effect with known anti-cancer drugs.
Rexahn has previously been awarded patents for quinoxalinyl-piperazine
compounds in Europe, Australia, Canada and Mexico.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in